[Disclosure] Celltrion (068270) Corrects and Finalizes 2023 Fiscal Year-End Cash Dividend to Approximately KRW 103.6 Billion

Fact Source: Financial Supervisory Service (DART) / 2024-03-26

Disclosure Type: (Amendment) Decision on Cash/In-kind Dividend

💡 3-Second Summary

Celltrion has corrected its fiscal year-end cash dividend to approximately KRW 103.6 billion (KRW 500 per common share) to reflect the finalized number of eligible outstanding shares and set the annual general meeting date.

📊 1. [Summary of Core Disclosure Content and Major Figures]

• Reason for Amendment: Corrections made to the total dividend amount, eligible share count, and annual general meeting (AGM) date.
• Key Dividend Metrics and Amendment Details (Before → After):
  • Total Dividend Amount: KRW 103,603,075,500 → KRW 103,603,764,500 (An increase of KRW 689,000)
  • Eligible Shares for Dividend: 207,206,151 shares → 207,207,529 shares
  • ※ Calculation Base: Derived by subtracting treasury shares from the total outstanding shares of the merged entity (220,290,520 shares) following the merger of Celltrion and Celltrion Healthcare.
    • Treasury shares subtracted (Before): 13,084,369 shares
    • Treasury shares subtracted (After): 13,082,991 shares (A minor change in treasury shares led to the adjustments in eligible shares and total payout)
  • Scheduled AGM Date: Undecided → March 26, 2024
• Dividend Specifications:
  • Dividend Class and Type: Fiscal year-end dividend / Cash dividend (Disproportionate dividend: No)
  • Dividend per Share: KRW 500 per common share (No preferred shares)
  • Dividend Yield to Market Price: 0.3% for common stock
  • Dividend Baseline Date (Record Date): December 31, 2023
  • Expected Dividend Payment Date: Scheduled to be paid within one month following the approval at the AGM pursuant to Article 464-2 of the Commercial Act.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

• Minor Adjustment Based on Eligible Share Count: This filing clarifies that following the initial dividend announcement on December 13, 2023, the number of subtracted treasury shares decreased slightly from 13,084,369 to 13,082,991, resulting in a minor increase of 1,378 in the eligible share count and a corresponding adjustment in the final dividend payout.
• Reflecting Post-Merger Capital Structure: The dividend calculation utilizes the capital structure of the newly merged entity, calculating the payout based on the combined outstanding shares of 220,290,520 minus the finalized treasury share count of 13,082,991.
• No Financial Performance Causes Specified: This filing reports modifications to the previously determined cash dividend. It does not contain any details on historical financial performance fluctuations or operational causes.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion’s amended filing represents the final administrative adjustment of its 2023 year-end cash dividend (KRW 500 per share) prior to execution, integrating the post-merger treasury share count and establishing March 26, 2024, as the official AGM date. Reflecting a minor increase in the number of eligible shares, the total dividend payout has been finalized at approximately KRW 103.6 billion.

For investors reviewing this announcement, the primary operational check is the ‘actual timing of the dividend distribution.’ In accordance with Article 464-2 of the Commercial Act, the payout must be disbursed within one month following approval at the AGM. Investors should track the official resolution of the AGM and verify the subsequent announcement of the final payment date systematically and factually.

📢 Disclaimer & Source Information

Source: This content was restructured and newly drafted based on the official submitted data from the Financial Supervisory Service (DART).

Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the individual investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.